TABLE 3.
Antiviral activity of pyridine oxide derivatives against different HIV strains in CEM cell cultures
| Compound | EC50 (μg/ml)a
|
||||
|---|---|---|---|---|---|
| HIV-1 strain
|
HIV-2 strain
|
||||
| RF | MN | HE | ROD | EHO | |
| JPL-10 | 7.2 ± 2.6 | 10 ± 1 | 11 ± 4 | 10 ± 1 | 14 ± 1 |
| JPL-27 | 10 ± 2 | 13 ± 1 | 10 ± 2 | 12 ± 2 | 14 ± 2 |
| JPL-30 | 10 ± 1 | 40 ± 4 | 38 ± 2 | 40 ± 4 | 44 ± 5 |
| JPL-71 | 0.3 ± 0.1 | 1.4 ± 0.3 | 0.4 ± 0.1 | >20 | >20 |
| JPL-74 | 1.0 ± 0.3 | ≥4b | ≥4b | >4b | >4b |
| JPL-78 | 7.7 ± 3.3 | 36 ± 16 | 17 ± 10 | >100 | >100 |
| JPL-107 | 1.1 ± 0.6 | 2.4 ± 0.2 | 4 ± 1 | >4b | >4b |
| JPL-110 | 48 ± 10 | 60 ± 1 | 40 ± 9 | >100 | >100 |
| JPL-133 | 0.16 ± 0.10 | 0.4 ± 0.1 | 0.2 ± 0.1 | >20 | ≥20 |
| JPL-146 | 8.4 ± 0.5 | 13 ± 1 | 10 ± 2 | ≥20 | >20 |
| JPL-150 | 8.4 ± 0.5 | 20 ± 4 | 14 ± 1 | >20 | >20 |
a
EC50, compound concentration required to inhibit HIV-1-induced cytopathicity (giant cell formation) in CEM cell cultures. Data represent the average values (± standard deviation) for at least three independent experiments.
b
Higher drug concentrations could not be accurately determined due to insolubility of the compound at these concentrations.